Brief Report: Dystrophin Immunity in Duchenne's Muscular Dystrophy.

被引:455
|
作者
Mendell, Jerry R. [2 ,3 ]
Campbell, Katherine [1 ,3 ]
Rodino-Klapac, Louise [2 ,3 ]
Sahenk, Zarife [2 ,3 ]
Shilling, Chris [2 ]
Lewis, Sarah [2 ]
Bowles, Dawn [4 ]
Gray, Steven [4 ]
Li, Chengwen [4 ]
Galloway, Gloria [2 ]
Malik, Vinod [2 ]
Coley, Brian [2 ]
Clark, K. Reed [2 ]
Li, Juan [5 ]
Xiao, Xiao [5 ]
Samulski, Jade [6 ]
McPhee, Scott W. [6 ]
Samulski, R. Jude [4 ]
Walker, Christopher M. [1 ,3 ]
机构
[1] Nationwide Childrens Hosp, Ctr Vaccines & Immun, Res Inst, Columbus, OH 43205 USA
[2] Nationwide Childrens Hosp, Ctr Gene Therapy, Res Inst, Columbus, OH 43205 USA
[3] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA
[4] Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC USA
[5] Univ N Carolina, Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC USA
[6] Asklepios BioPharmaceut, Chapel Hill, NC USA
关键词
GENE-TRANSFER; CONGENITAL AMAUROSIS; MUSCLE; REARRANGEMENTS; DEGENERATION; RESPONSES; THERAPY; HUMANS; TRIAL; MICE;
D O I
10.1056/NEJMoa1000228
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We report on delivery of a functional dystrophin transgene to skeletal muscle in six patients with Duchenne's muscular dystrophy. Dystrophin-specific T cells were detected after treatment, providing evidence of transgene expression even when the functional protein was not visualized in skeletal muscle. Circulating dystrophin-specific T cells were unexpectedly detected in two patients before vector treatment. Revertant dystrophin fibers, which expressed functional, truncated dystrophin from the deleted endogenous gene after spontaneous in-frame splicing, contained epitopes targeted by the autoreactive T cells. The potential for T-cell immunity to self and nonself dystrophin epitopes should be considered in designing and monitoring experimental therapies for this disease. (Funded by the Muscular Dystrophy Association and others; ClinicalTrials.gov number, NCT00428935.).
引用
收藏
页码:1429 / 1437
页数:9
相关论文
共 50 条
  • [41] SURAMIN ATTENUATES DYSTROPHIN-DEFICIENT CARDIOMYOPATHY IN THE mdx MOUSE MODEL OF DUCHENNE MUSCULAR DYSTROPHY
    Moreira, Drielen De Oliveira
    Pereira, Juliano Alves
    Tiemi Taniguti, Ana Paula
    Matsumura, Cintia Yuri
    Ferreira Ramos, Luis Alberto
    Areas, Miguel Arcanjo
    Neto, Humberto Santo
    Marques, Maria Julia
    MUSCLE & NERVE, 2013, 48 (06) : 911 - 919
  • [42] miRNAs as serum biomarkers for Duchenne muscular dystrophy
    Cacchiarelli, Davide
    Legnini, Ivano
    Martone, Julie
    Cazzella, Valentina
    D'Amico, Adele
    Bertini, Enrico
    Bozzoni, Irene
    EMBO MOLECULAR MEDICINE, 2011, 3 (05) : 258 - 265
  • [43] Determining neurodevelopmental manifestations in Duchenne muscular dystrophy using a battery of brief tests
    Saito, Yoshihiko
    Takeshita, Eri
    Komaki, Hirofumi
    Nishino, Ichizo
    Sasaki, Masayuki
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2022, 440
  • [44] Skeletal Muscle Differentiation on a Chip Shows Human Donor Mesoangioblasts' Efficiency in Restoring Dystrophin in a Duchenne Muscular Dystrophy Model
    Serena, Elena
    Zatti, Susi
    Zoso, Alice
    Lo Verso, Francesca
    Tedesco, F. Saverio
    Cossu, Giulio
    Elvassore, Nicola
    STEM CELLS TRANSLATIONAL MEDICINE, 2016, 5 (12) : 1676 - 1683
  • [45] Expression and function of four AAV-based constructs for dystrophin restoration in the mdx mouse model of Duchenne muscular dystrophy
    Potter, Rachael A.
    Griffin, Danielle A.
    Heller, Kristin N.
    Mendell, Jerry R.
    Rodino-Klapac, Louise R.
    BIOLOGY OPEN, 2023, 12 (09):
  • [46] Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy
    Siemionow, M.
    Cwykiel, J.
    Heydemann, A.
    Garcia-Martinez, J.
    Siemionow, K.
    Szilagyi, E.
    STEM CELL REVIEWS AND REPORTS, 2018, 14 (02) : 189 - 199
  • [47] Evolving Paradigms in Clinical Pharmacology and Therapeutics for the Treatment of Duchenne Muscular Dystrophy
    Huard, J.
    Mu, X.
    Lu, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (02) : 142 - 146
  • [48] The Implication of Hinge 1 and Hinge 4 in Micro-Dystrophin Gene Therapy for Duchenne Muscular Dystrophy
    Wasala, Lakmini P.
    Watkins, Thais B.
    Wasala, Nalinda B.
    Burke, Matthew J.
    Yue, Yongping
    Lai, Yi
    Yao, Gang
    Duan, Dongsheng
    HUMAN GENE THERAPY, 2023, 34 (9-10) : 459 - 470
  • [49] MicroRNAs Involved in Molecular Circuitries Relevant for the Duchenne Muscular Dystrophy Pathogenesis Are Controlled by the Dystrophin/nNOS Pathway
    Cacchiarelli, Davide
    Martone, Julie
    Girardi, Erika
    Cesana, Marcella
    Incitti, Tania
    Morlando, Mariangela
    Nicoletti, Carmine
    Santini, Tiziana
    Sthandier, Olga
    Barberi, Laura
    Auricchio, Alberto
    Musaro, Antonio
    Bozzoni, Irene
    CELL METABOLISM, 2010, 12 (04) : 341 - 351
  • [50] In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers
    Chen, Menglong
    Shi, Hui
    Gou, Shixue
    Wang, Xiaomin
    Li, Lei
    Jin, Qin
    Wu, Han
    Zhang, Huili
    Li, Yaqin
    Wang, Liang
    Li, Huan
    Lin, Jinfu
    Guo, Wenjing
    Jiang, Zhiwu
    Yang, Xiaoyu
    Xu, Anding
    Zhu, Yuling
    Zhang, Cheng
    Lai, Liangxue
    Li, Xiaoping
    GENOME MEDICINE, 2021, 13 (01)